Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain NKTR message board posts where the ticker symbol NKTR has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest NKTR SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-046722 Size: 6 KB
2019-08-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-046720 Size: 6 KB
2019-08-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-046718 Size: 5 KB
2019-08-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-046715 Size: 6 KB
2019-08-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-046714 Size: 5 KB
2019-08-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-046428 Size: 9 KB
2019-08-16
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-19-001669 (34 Act)  Size: 8 KB
2019-08-12 005-45385
191014712
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000906709-19-000006 (34 Act)  Size: 5 MB
2019-08-09 000-24006
191011071
8-K  Documents   Interactive Data Current report, items 2.02 and 9.01
Acc-no: 0001213900-19-014971 (34 Act)  Size: 332 KB
2019-08-08 000-24006
191010244
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-043289 Size: 21 KB
2019-07-25
More NKTR SEC Filings


Related news from
Sun, 25 Aug 2019
19:06:45 +0000
The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend
The biotech space saw a few FDA decisions and clinical readouts over the last week.  The FDA handed down two verdicts, backing Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV )'s novel antibiotic while turning ...
Fri, 23 Aug 2019
19:00:00 +0000
INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar”  or the Company”) (NKTR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between  February 15, 2019 through August 8, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Fri, 23 Aug 2019
14:55:00 +0000
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Nektar failed to comply with commonly accepted good manufacturing processes.
Thu, 22 Aug 2019
23:30:00 +0000
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NKTR) in the United States District Court for the Northern District of California on behalf of those who purchased or acquired the securities of Nektar between February 15, 2019 through August 8, 2019, inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.
Thu, 22 Aug 2019
14:29:00 +0000
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”), are encouraged to contact the firm before October 18, 2019. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.
Wed, 21 Aug 2019
20:52:00 +0000
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2019 and August 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before October 18, 2019. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.
Wed, 21 Aug 2019
20:35:24 +0000
NEKTAR THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Northern District of California against Nektar Therapeutics, Inc.
that a federal securities class action lawsuit  has been filed in the United States District Court for the Northern District of California on behalf of all investors that purchased Nektar Therapeutics, Inc. (NKTR) (the “Company”) securities between February 15, 2019 and August 8, 2019 (the "Class Period"), inclusive. Investors who purchased the shares of Nektar Therapeutics, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.If you have incurred losses in the shares of Nektar Therapeutics, Inc., you may, no later than October 18, 2019, request that the Court appoint you lead plaintiff of the proposed class.
Wed, 21 Aug 2019
15:01:00 +0000
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics – NKTR
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics from February 15, 2019 through August 8, 2019, inclusive .
Wed, 21 Aug 2019
00:00:00 +0000
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm
NEW YORK, Aug. 20, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all investors that purchased Nektar Therapeutics, Inc. (NKTR) securities between February 15, 2019 and August 8, 2019 (the "Class Period").  Investors have until October 18, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit. On August 8, 2019, the company revealed that a manufacturing issue caused two batches of bempegaldesleukin to differ from the other twenty batches that were produced.
Tue, 20 Aug 2019
17:31:00 +0000
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). Nektar investors have until October 18, 2019 to file a lead plaintiff motion. Investors suffering losses on their Nektar investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
Tue, 20 Aug 2019
01:43:00 +0000
Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR)
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Damiba v. Nektar Therapeutics, et. al., (Case No. 3:19-cv-05173) on behalf of persons and/or entities that acquired Nektar Therapeutics (NASDAQ: NKTR) (“Nektar” or the “Company”) securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.
Fri, 16 Aug 2019
00:35:00 +0000
Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm
NEW YORK , Aug. 15, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against Nektar Therapeutics, Inc. (NASDAQ: NKTR). Our investigation concerns whether Nektar has violated ...
Thu, 15 Aug 2019
09:22:53 +0000
Edited Transcript of NKTR earnings conference call or presentation 8-Aug-19 9:00pm GMT
Q2 2019 Nektar Therapeutics Earnings Call
Wed, 14 Aug 2019
14:00:00 +0000
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR)
NEW YORK , Aug. 14, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Nektar Therapeutics ("Nektar" or ...
Tue, 13 Aug 2019
19:06:00 +0000
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nektar admitted on August 8, 2019, that it had suffered manufacturing problems resulting in two batches of Bempegaldesleukin differing from the other 20 batches produced.
Mon, 12 Aug 2019
18:20:55 +0000
Nektar Erases $1.8 Billion of Value on Doubts Over Its Cancer Drug
(Bloomberg) -- Investors sentiment on Nektar Therapeutics has soured as a manufacturing snafu raised concern about what had initially been seen as promising clinical data for its experimental cancer drug bempegaldesleukin.As Wall Street analysts continue to debate the drug’s potential, investors are fleeing fast. The stock fell 8% on Monday, bringing its two-day loss to 36%, or about $1.8 billion of market value. Nektar is now 2019’s worst performer in the S&P 500, after taking the top spot shortly after joining the benchmark last year.Some bulls have already backpedaled after the company also said it’s collaboration with Bristol-Myers Squibb Co. has narrowed to fewer studies, and lung cancer data won’t be presented at the ESMO conference in Barcelona next month.Nektar has seen three downgrades just last week, with the number of hold or equivalent ratings rising to a total of six. Eight other analysts who cover the stock stood by their bullish recommendations.The debate over bempegaldesleukin, formerly known as NKTR-214, is set to continue until the company reports first results from its late-stage studies, which are not expected until next year.To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Mon, 12 Aug 2019
16:29:00 +0000
Why Nektar Therapeutics Stock Is Falling Again Today
The biotech continues to feel the repercussions from news announced last week.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2019, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards